Welcome to our dedicated page for Guardant Health SEC filings (Ticker: GH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Guardant Health, Inc. filings document a Nasdaq-listed precision oncology company that reports results for Oncology, Screening, and Biopharma & Data activities. Its 8-K filings furnish quarterly and annual financial results, preliminary financial information, Regulation FD presentation materials, material agreements, officer changes, and securities offering disclosures.
The company’s proxy materials cover annual meeting voting matters, board and governance information, executive compensation and stockholder proposals. Registration and offering-related filings describe common stock issuance under a shelf registration statement, while recurring disclosures address capital structure, operating outlook, clinical and regulatory updates, and the use of its blood and tissue testing portfolio.
Guardant Health, Inc. (GH) has an officer, Kumud Kalia, filing a Rule 144 notice to sell 4,000 shares of common stock of Guardant Health through Charles Schwab & Co., Inc. The planned sale, listed on NASDAQ, is tied to shares acquired via equity compensation between April 1, 2025 and October 1, 2025.
The filing also reports that Kalia previously sold 3,418 shares of Guardant Health common stock on June 11, 2026 for aggregate proceeds of $445,156. The new 4,000-share sale is valued in the notice at $632,193 as of September 11, 2026.
Guardant Health, Inc. (GH) reported insider transactions by Co-Chief Executive Officer and director Helmy Eltoukhy involving only indirect holdings. On August 26, 2026, entities associated with him restructured 50,000 shares of common stock, moving 25,000 shares from the Helmy A. Eltoukhy Revocable Trust to The Eltoukhy Foundation, leaving the foundation holding 60,000 shares. The same trust also made a bona fide gift of 30,000 shares to a Donor Advisory Fund at Vanguard. All transactions were reported at a price of $0.00 per share and reflect ownership changes and charitable giving rather than market purchases or sales.
Guardant Health, Inc. (GH) reported that Co-Chief Executive Officer and director AmirAli Talasaz, through indirect ownership by the Talasaz Family Foundation, sold a total of 37,500 shares of common stock on August 21, 2026 in open-market or private transactions. The sales occurred in three weighted-average price tranches between $167.81 and $170.50 per share. The transactions were not reported as made under a Rule 10b5-1 trading plan.
Guardant Health, Inc. (GH) director Roberto Mignone reported the vesting and settlement of equity awards. On August 21, 2026, 264 Restricted Stock Units were converted into 264 shares of Common Stock at $0.00 per share. Following these transactions, he holds 10,010 Common shares and 6,864 RSUs, all as direct ownership. The RSUs were from a November 8, 2024 grant that vests over four years, with 25% vesting on October 21, 2025 and the remaining 75% vesting monthly over the next three years.
Guardant Health, Inc. (GH) received a Rule 144 notice relating to proposed sales of its common stock for the account of officer AmirAli Talasaz. The notice covers up to 37,500 shares, described as founder shares acquired from the issuer on September 22, 2018, with sales to be effected through Stifel Nicolaus & Company Inc. The filing also lists prior sales of Guardant Health common stock by AmirAli Talasaz over the past three months.
Guardant Health, Inc. (GH) director Manuel Hidalgo Medina reported the vesting and conversion of restricted stock units into common stock. On August 17, 2026, 232 restricted stock units were converted into 232 shares of common stock at an exercise price of $0.00 per share. Following these transactions, he held 4,788 shares of common stock directly and 5,337 restricted stock units, which continue to vest under an award granted on July 17, 2024.
Guardant Health, Inc. (GH) director Tariq Musa reported a combination of RSU vesting and share sales. On August 15, 2026, 250 Restricted Stock Units were converted into 250 shares of common stock, increasing direct holdings to 1,749 shares. On August 17, 2026, he sold 116 common shares at $156.45 per share in an open-market or private transaction. The RSU award was granted on March 6, 2023 and vests over four years, with 25% vested March 15, 2024 and the remaining 75% vesting monthly over the following three years. The filing indicates these transactions were effected under a Rule 10b5-1 trading plan.
Musa Tariq filed a notice to sell 116 shares of Guardant Health, Inc. common stock through Charles Schwab & Co., Inc., with an aggregate market value of $18,148.00, on or after August 17, 2026 on NASDAQ. The shares arise from a Restricted Stock Lapse tied to equity compensation that occurred on July 15, 2026. The filing also lists prior sales of Guardant Health common stock over the past three months.
T. Rowe Price Associates, Inc. reported beneficial ownership of common stock of Guardant Health, Inc.. The firm held 6,514,828 shares of Guardant Health common stock, representing 4.9% of the class as of June 30, 2026.
T. Rowe Price reported sole voting power over 6,359,951 shares and sole dispositive power over 6,514,828 shares, with no shared voting or dispositive power. The filer expressly denied that this filing should be construed as an admission of beneficial ownership of these securities.
Guardant Health, Inc. executive Terilyn J. Monroe, Chief People Officer, exercised stock options covering 46,300 shares of common stock on 2026-08-12 (32,288 shares at an exercise price of $20.14 and 14,012 shares at $28.61). She then sold 46,300 common shares in multiple open-market or private transactions at weighted average prices ranging from $162.80 to $168.02. The exercised options were from awards granted on February 26, 2024 and November 8, 2024, each vesting over three years with 33% vesting after roughly one year and the remaining 67% in equal monthly installments over the next two years. The filing does not affirm trading under a Rule 10b5-1 plan.